3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
7
NIH
2
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Recurrent Squamous Cell Lung Carcinoma
2
Melanoma
2
Small Cell Lung Carcinoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Inoperable Åsophageal Cancer
1
Gastric and Esophagogastric Junction Adenocarcinoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Dexamethasone
45
Bortezomib
21
Lenalidomide
19
Cyclophosphamide
19
daratumumab
16
Calcium Dobesilate
13
Thalidomide
12
Melphalan
11
carfilzomib
9
Prednisone
7
pomalidomide
6
Peripheral Blood Stem Cell Transplantation
6
Doxorubicin
6
Filgrastim
5
dexamethasone acetate
4
dexamethasone 21-phosphate
4
auricularum
4
Vincristine
4
isatuximab
3
Interferon-alpha
3
Etoposide
3
selinexor
2
sargramostim
2
ixazomib
2
elotuzumab
2
cobimetinib
2
Steroids
2
Radiotherapy
2
Microarray Analysis
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Multiple Myeloma
×
Ipilimumab
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled